An interventional study of Fetal Treatment arm (FETO Group) in Congenital Diaphragmatic Hernia, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.
Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 4th largest by planned enrollment of the 36 interventional ones that give a count, is one of 7 that started in 2025, is one of 28 with no phase, reaches primary completion later than 16 of the 27 other live ones, and was the 37th registered.
86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.
Browse Hernias, Diaphragmatic, Congenital studies →24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:
Mauro H. Schenone · Sites in United States
Ages 18–50 · Women only
Dr Erin Perrone · Sites in United States
Ages 18+
Vincent Duron · Sites in United States
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 0 mo–1 mo
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 30 across 62 interventional studies indexed under Hernias, Diaphragmatic, Congenital.
Median enrollment 21 across the 36 interventional studies, 51 across the 8 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 45 has an industry lead sponsor. The 10 most frequent:
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
The University of Texas Health Science Center, Houston has 3 studies filed under Hernias, Diaphragmatic, Congenital — fewer than ten, so there is no comparison to draw.
2 of the studies in Hernias, Diaphragmatic, Congenital with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04583644Hanmin LeePilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH) | 2027-04 |
| NCT00950118Columbia UniversityDiaphragmatic Hernia Research & Exploration, Advancing Molecular Science | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate successful placement and removal of Fetoscopic Endoluminal Tracheal Occlusion (FETO) device in cases of intrathoracic liver herniation with isolated left congenital diaphragmatic hernia (LCDH) with Observed/Expected (O/E) Lung to Head Circumference Ratio (LHR) \< 30% or isolated right congenital diaphragmatic hernia (RCDH) with O/E LHR \< 45%,to compare survival to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation and isolated LCDH with O/E LHR \< 30% that receive FETO procedure performed at 27 weeks 0 days to 29weeks 6 days of gestation to those with intrathoracic liver herniation, isolated LCDH and o/e LRH \< 30% that undergo expectant management, to compare the neonatal survival rate to discharge from the neonatal intensive care units (NICU), between fetuses with intrathoracic liver herniation, isolated RCHD with o/e LHR \< 45% that undergo FETO procedure performed at 27 weeks 0 days to 29 weeks 6 days gestation to those with intrathoracic liver herniation, isolated RCHD and o/e LHR \< 45% that elect to proceed with expectant management, to evaluate the frequency of maternal and fetal complications associated with FETO procedure, to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated LCDH survivors with o/e LHR \<30% when compared to isolated LCDH with o/e LRH \<30% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation and to evaluate whether the FETO procedure is associated with reduced long-term mortality and morbidities in isolated RCDH survivors with o/e LHR ≤ 45% when compared to isolated RCHD with LHR \< 45% that undergo expectant management where all fetuses were found to have intrathoracic liver herniation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Psychosocial ineligibility, precluding consent:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Fetal Treatment arm (FETO Group)
Participants will undergo FETO surgery at at 27 weeks 0 days - 29 weeks 6 days gestation.Balloon insertion into the fetal trachea will be performed. This will be followed by weekly \\ ultrasound monitoring and MRI at 3 weeks following FETO insertion and removal of the balloon which will be performed at at 34 weeks 0 days to 34 weeks 6 days. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age
Number of neonates that survived
Time frame: from delivery to hospital discharge (up to 12 months)
Number of Successful placement of FETO device
Time frame: 10-60 minutes after surgery begins
Number of Successful removal of FETO device
Time frame: immediately after the procedure (about 1 hour after start of surgery)
FETO procedure complications
Complications include, Failure FETO insertion procedure, FETO device dislodgement potentially requiring a second FETO insertion, Fetal intraoperative injury, Procedural hemorrhage, Bleeding from insertion site or Abruptions, Post-procedural hemorrhage PPROM, Preterm delivery, Chorioamnion separation,Chorioamnionitis, Polyhydramnios, Oligohydramnios,Emergent removal due to obstetrical complication, Failed percutaneous or fetoscopic removal requiring cesarean section or exit procedure for removal, Neonatal death due to asphyxia if delivery before FETO removal and Non-reassuring fetal heart rate monitoring
Time frame: end of study (24 months)
Number of infants that survived
Time frame: 6 months
Number of infants that survived
Time frame: 12 months
Number of infants that survived
Time frame: 18 months
Number of infants that survived
Time frame: 24 months
Number of infants that show presence of pulmonary hypertension
Time frame: 6 months
Number of infants that show presence of pulmonary hypertension
Time frame: 12 months
Number of infants that show presence of pulmonary hypertension
Time frame: 18 months
Number of infants that show presence of pulmonary hypertension
Time frame: 24 months
Number of infants that show need for supplemental oxygen
Time frame: 6 months
Number of infants that show need for supplemental oxygen
Time frame: 12 months
Number of infants that show need for supplemental oxygen
Time frame: 18 months
Number of infants that show need for supplemental oxygen
Time frame: 24 months
Number of infants that show periventricular leukomalacia
Time frame: at less than 2 months postnatally
Number of Infants that develop sepsis
Time frame: 6 months
Number of Infants that develop sepsis
Time frame: 12 months
Number of Infants that develop sepsis
Time frame: 18 months
Number of Infants that develop sepsis
Time frame: 24 months
Number of infants that develop Intraventricular hemorrhage (grade 0-III)
Time frame: 6 months
Number of infants that develop Intraventricular hemorrhage (grade 0-III)
Time frame: 12 months
Number of infants that develop Intraventricular hemorrhage (grade 0-III)
Time frame: 18 months
Number of infants that develop Intraventricular hemorrhage (grade 0-III)
Time frame: 24 months
Number of infants that develop retinopathy of prematurity (grade 3 or higher)
Time frame: 6 months
Number of infants that develop retinopathy of prematurity (grade 3 or higher)
Time frame: 12 months
Number of infants that develop retinopathy of prematurity (grade 3 or higher)
Time frame: 18 months
Number of infants that develop retinopathy of prematurity (grade 3 or higher)
Time frame: 24 months
Number of infants that develop gastro-esophageal reflux
Time frame: 6 months
Number of infants that develop gastro-esophageal reflux
Time frame: 12 months
Number of infants that develop gastro-esophageal reflux
Time frame: 18 months
Number of infants that develop gastro-esophageal reflux
Time frame: 24 months
Number of infant hospital readmissions
Time frame: end of study (24 months)
Cause of infant hospital readmissions
Time frame: end of study (24 months)
Number of infants that show childhood growth failure
Time frame: 6 months
Number of infants that show childhood growth failure
Time frame: 12 months
Number of infants that show childhood growth failure
Time frame: 18 months
Number of infants that show childhood growth failure
Time frame: 24 months
Number of infants that show recurrence of CDH repair
Time frame: 6 months
Number of infants that show recurrence of CDH repair
Time frame: 12 months
Number of infants that show recurrence of CDH repair
Time frame: 18 months
Number of infants that show recurrence of CDH repair
Time frame: 24 months
Number of infants that develop bowel obstruction
Time frame: 6 months
Number of infants that develop bowel obstruction
Time frame: 12 months
Number of infants that develop bowel obstruction
Time frame: 18 months
Number of infants that develop bowel obstruction
Time frame: 24 months
Number of infants that show neurodevelopmental delay as assessed by the Bayley Scales of Infant and Toddler Development-III(BSID)
Three domains will be measured as follows: Cognitive Scale, Language Scale (Receptive and Expressive) and Motor Scale (Fine and Gross Motor Skills). Scores are derived by converting raw scores from completed tasks into scale scores and composite scores. These scores are then utilized to assess the child's performance in relation to norms established based on typically developing children of the same age Mean score of 100 (SD=15) at the 50th percentile signifies mid-average functioning. Scores below 85 (1 SD below the mean), at the 16th percentile, indicate mild impairment of being 'at risk' of developmental delay. Score below 70 (2 SD below the mean), at the second percentile, indicate moderate to severe impairment. In general, scores falling in the lowest 10th percentile indicate developmental delay
Time frame: 24 months
Number of infants that develop bronchopulmonary dysplasia
Time frame: 6 months
Number of infants that develop bronchopulmonary dysplasia
Time frame: 12 months
Number of infants that develop bronchopulmonary dysplasia
Time frame: 18 months
Number of infants that develop bronchopulmonary dysplasia
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2029, 56 months after the start.
Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 56 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hernias, Diaphragmatic, Congenital →
The University of Texas Health Science Center, Houston →